Transition From Alendronate to Romosozumab (AMG 785)
Status:
Completed
Trial end date:
2012-11-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the percent change from baseline in lumbar spine
bone mineral density (BMD) following multiple-dose administrations of romosozumab in
postmenopausal women with low BMD previously treated with alendronate.